OTTAWA (Reuters) - Canada said on Sunday it was giving privately held Canadian firm AbCellera Biologics Inc C$176 million to help it find naturally produced antibodies that could be used to battle the coronavirus outbreak.
Federal Innovation Minister Navdeep Bains said AbCellera had identified over 500 antibodies from a patient who has recovered from COVID-19.
“This funding is instrumental in accelerating and expanding AbCellera’s capabilities to combat COVID-19. AbCellera and its partners expect clinical trials to begin in July 2020 or earlier,” he said in a statement.
The money will also help the firm to build a Vancouver facility that can manufacture antibodies for clinical testing, he added.
AbCellera said in March it was working with Eli Lilly and Co to co-develop antibody products for the treatment and prevention of COVID-19, a flu-like disease caused by the coronavirus.
Reporting by David Ljunggren; Editing by Lisa Shumaker
Our Standards: The Thomson Reuters Trust Principles.